clozapine + haloperidol

Clozapine + haloperidol is a combination of two antipsychotic drugs used primarily in the management of treatment-resistant schizophrenia. Clozapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D1 receptors, as well as moderate antagonism at dopamine D2 receptors. It is particularly effective in patients who do not respond to other antipsychotics but carries risks such as agranulocytosis, sedation, and metabolic side effects. Haloperidol is a typical (first-generation) antipsychotic that acts mainly as a potent antagonist at dopamine D2 receptors, reducing psychotic symptoms by decreasing dopaminergic activity in the brain[8]. The combination may be considered when monotherapy with clozapine does not achieve adequate symptom control; however, this strategy should be approached cautiously due to increased risk of adverse effects including extrapyramidal symptoms and rare but serious complications like rhabdomyolysis[1][6][9]. Evidence suggests no significant long-term difference in efficacy between clozapine plus haloperidol versus other combinations for mental state improvement in treatment-resistant schizophrenia[1][6].